Jeong Gi Uk, Song Hanra, Yoon Gun Young, Kim Doyoun, Kwon Young-Chan
Center for Convergence for Emerging Virus Infection, Korea Research Institute of Chemical Technology (KRICT), Daejeon, South Korea.
Division of Therapeutics and Biotechnology, KRICT, Daejeon, South Korea.
Front Microbiol. 2020 Jul 14;11:1723. doi: 10.3389/fmicb.2020.01723. eCollection 2020.
The novel coronavirus, SARS-CoV-2, or 2019-nCoV, which originated in Wuhan, Hubei province, China in December 2019, is a grave threat to public health worldwide. A total of 3,672,238 confirmed cases of coronavirus disease 2019 (COVID-19) and 254,045 deaths were reported globally up to May 7, 2020. However, approved antiviral agents for the treatment of patients with COVID-19 remain unavailable. Drug repurposing of approved antivirals against other viruses such as HIV or Ebola virus is one of the most practical strategies to develop effective antiviral agents against SARS-CoV-2. A combination of repurposed drugs can improve the efficacy of treatment, and structure-based drug design can be employed to specifically target SARS-CoV-2. This review discusses therapeutic strategies using promising antiviral agents against SARS-CoV-2. In addition, structural characterization of potentially therapeutic viral or host cellular targets associated with COVID-19 have been discussed to refine structure-based drug design strategies.
新型冠状病毒，即严重急性呼吸综合征冠状病毒2（SARS-CoV-2），或2019新型冠状病毒（2019-nCoV），于2019年12月在中国湖北省武汉市出现，对全球公共卫生构成严重威胁。截至2020年5月7日，全球共报告了3672238例2019冠状病毒病（COVID-19）确诊病例和254045例死亡病例。然而，目前仍没有获批用于治疗COVID-19患者的抗病毒药物。将已获批的抗其他病毒（如艾滋病毒或埃博拉病毒）的抗病毒药物进行重新利用，是开发针对SARS-CoV-2的有效抗病毒药物的最实用策略之一。重新利用药物的组合可以提高治疗效果，基于结构的药物设计可用于特异性靶向SARS-CoV-2。本综述讨论了使用有前景的抗SARS-CoV-2抗病毒药物的治疗策略。此外，还讨论了与COVID-19相关的潜在治疗性病毒或宿主细胞靶点的结构特征，以完善基于结构的药物设计策略。
